Appendix C, Proof of Proposition 3, p. 37 — (∂W/∂β)/(∂M/∂β) − (∂W/∂α)/(∂M/∂α) = f₁/f₂ with f₂ > 0
ProvedRareDisease.ExogOutcome.marginal_ratemarginal-analysisp2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1subsidy
Let , and . With and the patient welfare and the government's expenditure of the reduced problem (20),
the partial derivatives satisfy
where
and .
Along the curve where the budget binds, the left-hand side measures the change in welfare per unit of expenditure when manufacturer subsidy is traded for patient subsidy; its sign is that of , which separates the regimes of Proposition 3.
Formalization Note Partial derivatives are Mathlib's deriv of the one-variable sections and (and likewise for ); both functions are differentiable at every policy, so these are the ordinary partial derivatives. The positivity is the paper's step "the sign of is equal to the sign of ".
Preamble
import Mathlib
Formal statement
namespace RareDisease.ExogOutcome
/-- Appendix C, Proof of Proposition 3, p. 37: with `W(α, β)` the patient welfare and
`M(α, β)` the government's expenditure of (20), for every policy `α, β ∈ [0,1)`,
`(∂W/∂β)/(∂M/∂β) - (∂W/∂α)/(∂M/∂α) = f₁/f₂` with
`f₁ = (1 - α)((5 - α) p - 2 (1 - α))(1 - (1 - β) p)` and
`f₂ = 2 p (1 + 2β + α - 2αβ)(1 + 2αp + 3βp - 3αβp - α - p)`, and `f₂ > 0`. -/
theorem marginal_rate (k p α β : ℝ) (hk : 0 < k) (hp0 : 0 < p) (hp1 : p < 1)
(hα : α ∈ Set.Ico (0 : ℝ) 1) (hβ : β ∈ Set.Ico (0 : ℝ) 1) :
let W : ℝ → ℝ → ℝ := fun α β => p * (1 - (1 - β) * p) ^ 3 / (4 * (1 - α) * k)
let M : ℝ → ℝ → ℝ := fun α β =>
α * p ^ 2 * (1 - (1 - β) * p) ^ 2 / (4 * (1 - α) ^ 2 * k)
+ β * p ^ 2 * (1 - (1 - β) * p) ^ 2 / (2 * (1 - α) * k)
let f₁ : ℝ := (1 - α) * ((5 - α) * p - 2 * (1 - α)) * (1 - (1 - β) * p)
let f₂ : ℝ := 2 * p * (1 + 2 * β + α - 2 * α * β)
* (1 + 2 * α * p + 3 * β * p - 3 * α * β * p - α - p)
deriv (fun β' => W α β') β / deriv (fun β' => M α β') β
- deriv (fun α' => W α' β) α / deriv (fun α' => M α' β) α = f₁ / f₂ ∧
0 < f₂ := by sorry
end RareDisease.ExogOutcome
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 37, Appendix C, Proof of Proposition 3
Human review
Confirmed by the mission captain (proposal self-audit).
Confirmed by the moderator at approval.